首页> 外文期刊>Infectious disease clinics of North America >Treatment of shiga toxin-producing escherichia coli infections
【24h】

Treatment of shiga toxin-producing escherichia coli infections

机译:滋阴生产大肠杆菌感染治疗滋阴毒素

获取原文
获取原文并翻译 | 示例
           

摘要

The management of Shiga toxin-producing Escherichia coli (STEC) infections is reviewed. Certain management practices optimize the likelihood of good outcomes, such as avoidance of antibiotics during the pre-hemolytic uremic syndrome phase, admission to hospital, and vigorous intravenous volume expansion using isotonic fluids. The successful management of STEC infections is based on recognition that a patient might have an STEC infection, and appropriate use of the microbiology laboratory. The timeliness of STEC identification cannot be overemphasized, because it avoids therapies prompted by inappropriate additional testing and directs the clinician to focus on effective management strategies. The opportunities during STEC infections to avert the worst outcomes are brief, and this article emphasizes practical matters relevant to making a diagnosis, anticipating the trajectory of illness, and optimizing care.
机译:综述了滋阴生产大肠杆菌(STEC)感染的滋阴生产的管理。 某些管理措施优化了良好结果的可能性,例如在溶血前尿毒症综合征期间避免抗生素,进入医院,使用等渗液体的剧烈静脉体积膨胀。 STEC感染的成功管理是基于识别,即患者可能具有STEC感染,以及适当使用微生物学实验室。 STEC识别的及时性不能赘述,因为它避免了不适当的额外测试提示疗法,并指导临床医生专注于有效的管理策略。 STEC感染期间避免最糟糕的结果的机会是简短的,这篇文章强调了与诊断有关的实际问题,期待疾病的轨迹,以及优化护理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号